# Moderna's mRNA RSV Vaccine Approved by FDA for Older Adults



Moderna announced that the U.S. Food and Drug Administration (FDA) has approved its respiratory syncytial virus (RSV) vaccine, mRESVIA, for people aged 60 years and older. This approval marks Moderna's second product using its mRNA technology platform, similar to its COVID-19 vaccine approved in December 2020. Stéphane Bancel, CEO of Moderna, highlighted the significance of mRESVIA as the first mRNA vaccine approved to address a disease other than COVID-19.

RSV is known to cause severe respiratory issues, particularly in older adults. The Centers for Disease Control and Prevention (CDC) reports that RSV hospitalizes between 60,000 and 160,000 U.S. adults annually, and results in 6,000 to 10,000 deaths. Moderna’s vaccine will compete with GSK’s Arexvy and Pfizer’s Abrysvo, both of which were approved last year for the same age group.

Moderna projects mRESVIA will generate $4.6 billion in global sales over the next five years, though analysts estimate higher sales predictions for GSK and Pfizer's RSV vaccines. Moderna also emphasized that mRESVIA is the only pre-filled syringe vaccine for RSV, potentially enhancing administration efficiency.

The company aims to diversify its portfolio beyond COVID-19 products. Moderna’s current pipeline includes late-stage trials for vaccines targeting melanoma, cytomegalovirus (CMV), and a combined COVID and flu shot. Analysts suggest that the RSV vaccine approval could bolster Moderna’s financial stabilization and growth efforts.